Jennifer Brown, MD, PhD discusses results form the ALPINE trial

Name: Jennifer Brown, MD, PhD discusses results form the ALPINE trial
Uploaded: 2025-12-18T00:00:00+00:00
Description: Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Published

December 18, 2025

Created by

Related Presenters

Jennifer Brown, MD, PhD

Medical Oncology

View Full Profile

Related Videos

Video

Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling

Video

Reid W. Merryman, MD discusses results of a multicenter phase II trial

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma

Video

Jacqueline Garcia, MD discussed results from the Phase # VERONA study

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacititine (Pbo+Aza) in patients with treatment-naive, intermediate and higher-risk Myelodysplastic Syndromes (HR-MDS)

Video

Austin Kim, MD discusses phase I/II study

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Video

Omar Nadeem, MD discusses results of the Phase II d-PRISM study

Daratumumab in high-rish MGUS and low-risk smoldering myeloma

Video

Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenstrom macroglobulinemia

Video

Marlise Luskin, MD, MSCE discusses results of a phase 1 trial

Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial

Video

Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study

Phase 2 Study of post transplant cyclophosphamide-based graft versus host disease prophlaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning

Video

Shayna Sarosiek, MD discusses WM-NET 1 trial

Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.